Traws Pharma, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Traws Pharma, Inc. (TRAW) had Deferred Tax Assets, Operating Loss Carryforwards of $29.86 million as of 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-04-15
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $29.86M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $28.32M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $74.03M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $73.39M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $29.86M 10-K · filed 2026-04-15 | |
| 2024-12-31 | $28.32M 10-K · filed 2026-04-15 | |
| 2023-12-31 | $74.03M 10-K · filed 2025-03-31 | |
| 2022-12-31 | $73.39M 10-K · filed 2024-04-01 | |
| 2021-12-31 | $81.47M 10-K · filed 2023-03-30 | |
| 2020-12-31 | $76.63M 10-K · filed 2022-03-21 | |
| 2019-12-31 | $69.64M 10-K · filed 2021-03-18 | |
| 2018-12-31 | $57.56M 10-K · filed 2020-03-27 | $63.49M 10-K · filed 2019-04-01 |
| 2017-12-31 | $57.56M 10-K · filed 2019-04-01 | |
| 2016-12-31 | $75.83M 10-K · filed 2018-03-16 | |
| 2015-12-31 | $73.65M 10-K · filed 2017-03-29 | |
| 2014-12-31 | $63.78M 10-K · filed 2016-03-28 | |
| 2013-12-31 | $47.36M 10-K · filed 2015-03-30 | |
| 2012-12-31 | $35.92M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |